Page 3 - Glaxosmithkline

GSK buys 10% stake of German biotech firm CureVac in $164-million deal

GSK and CureVac, backed by Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases, they said.

Covid-19 crisis: HUL hints at margin pressures, higher operating costs

"Distribution costs have significantly increased and there will be short-term pressure on margins," Sanjiv Mehta, chairman and managing director said.

Second-generation Covid-19 vaccines are built for impact over speed

Some of the world's most prolific and experienced vaccine developers -- Sanofi, GlaxoSmithKline and Merck & Co - are among at least 100 challengers trailing the leaders

J&J to begin human trials of Covid-19 vaccine in second half of July

The company has already signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021

GlaxoSmithKline Q4 consolidated net profit declines 6% to Rs 138 cr

The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.

Coronavirus vaccine not coming for at least 2 years: Novartis global CEO

A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts

GSK sells its entire 5.7% holding in HUL for over Rs 25,000 crore

More than 133 million shares of HUL were sold in the Rs 1,900-1,950 range, via multiple large transactions in morning trade

GSK to offload HUL stake worth Rs 26,000 cr in largest secondary sale

Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window

GlaxoSmithKline plans sale of $3.7-billion stake in Hindustan Unilever

The firm may offload part or all of its 5.7% holding in HUL through a series of block trades

GlaxoSmithKline, Sanofi strike deal to develop coronavirus vaccine

The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year.

Merger complete, focus now shifts to integration of HUL-GSK operations

The merger will also give HUL access to brands such as Horlicks and Boost, pitting the company against rivals such as Nestle India, another big player in the health and nutrition segment.

GSK Consumer merger sets stage for Hindustan Unilever, Nestle face-off

The NCLT nod paves the way for the final leg of the merger process, including an announcement of the record date (of the merger) and share allotment

Glaxo Consumer reports 6% rise in profit before tax for December quarter

The firm's operating revenue stood at Rs 1,159 crore - up 3.7 per cent YoY from Rs 1,117 crore

GSK credits STEER for Horlicks technology after year-long IP battle

STEER which was founded in 1993 by Padmanabhan has 5 global offices and 10 satellite offices, serving over 39 countries. It employs over 500 engineers, scientists and technicians across the globe

India considers incentives for Tesla, 323 others to set up shop in country

The Prime Minister's Office is considering the proposal and a decision is expected soon

GSK Consumer's pre-tax profit up 6% in Q2 on controlled raw material costs

According to the company, its domestic business grew 7 per cent, backed by Horlicks' and Boost's performance

GSK suspends sale of antacid Zinetac after USFDA issues advisory

Indian drugmakers have also started testing their ranitidine products at various laboratories after the US FDA issued an advisory on the drug to health care professionals

Drug major GSK sold off up to 10 tail-end brands in FY19 including Celin

According to the firm's FY19 annual report, it fetched Rs 5 crore during the year from the sale of brands

Bharat Biotech to buy GSK's Indian arm that produces anti-rabies vaccine

Bharat Biotech chairman Krishna Ella said the acquisition of Chiron Behring would make the company world's largest producer of anti-rabies vaccine

Pfizer Inc deal with GlaxoSmithKline plc will have no India impact

Ruling out any impact on GSK's India business, company sources said in India the pharma entity owned and manufactured products such as Iodex and Ostocalcium, which were marketed by GSK Consumer